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Rheumatoid Arthritis
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Chinese Herbal Medicine Program, Division of Research and Development, Development Center for
Biotechnology, Taipei, Taiwan, ROC
Plectranthus amboinicus (P. amboinicus) is a folk herb that is used to treat inflammatory
diseases or swelling symptoms in Taiwan. We investigated therapeutic efficacy of P. amboinicus
in treating Rheumatoid Arthritis (RA) using collagen-induced arthritis animal model. Arthritis
was induced in Lewis rats by immunization with bovine type II collagen. Serum anti-collagen
IgG, IgM and C-reactive protein (CRP) were analyzed. To understand the inflammation
condition of treated animals, production of TNF-a, IL-6 and IL-1b from peritoneal exudates
cells (PEC) were also analyzed. P. amboinicus significantly inhibited the footpad swelling and
arthritic symptoms in collagen-induced arthritic rats, while the serum anti-collagen IgM and
CRP levels were consistently decreased. The production of pro-inflammatory cytokines TNF-a,
IL-6 and IL-1b were also decreased in the high dosage of P. amboinicus group. Here, we
demonstrate the potential anti-arthritic effect of P. amboinicus for treating RA, which
might confer its anti-rheumatic activity. This differs the pharmacological action mode of
indomethacin.
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Introduction
Rheumatoid arthritis (RA) is an autoimmune disease that
causes chronic inflammation in synovial tissue and joints,
which leads to impaired joint function, severe pain and
reduced life expectancy (1). This disease affects about 1%
of the human population. The etiology and pathogenesis
of this disease are not yet fully understood but it seems
likely that an autoimmune-mediated attack on joints
plays a crucial role in RA (2). In brief, inflammation
and bone destruction may occur uncoupled. Therefore,
therapeutic agents developed for anti-inflammatory and
immunosuppressant activity will be useful and indispen-
sable for RA therapy. Currently, non-steroidal anti-
inflammatory drugs (NSAIDs) such as indomethacin and
celecoxib are commonly used to treat RA disease (3,4).
However, these drugs produce strong alleviative effect
including gastric ulcer and dysfunction or the risk of
cardiovascular disease (5,6). Although a panel of drugs
has been developed for the treatment of RA, therapies
for RA are not satisfied with these marketed drugs.
P. amboinicus belonging to the to Lamiaceae family, is
a perennial with a 3- to 10-years life span, and is
distributed in Tropical Africa, Asia and Australia, is used
as food, additive and fodder, and especially as medicine
in treating a wide range of diseases (7). For chemical
composition of P. amboinicus as an aqueous extract, the
major components are -3-carene, g-terpinene, camphor
and carvacrol (8). The leaf extract of P. amboinicus was
externally used in the skin allergy in India (9). In Taiwan,
P. amboinicus is used to treat inflammatory disease or
swelling symptoms based on historical experiences (10).
Furthermore, P. amboinicus is traditionally used treating
RA, which involved oral consumption wherein 50–70ml
of P. amboinicus extract was consumed daily. However,
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properly cited.there is no scientific evidence to prove the effectiveness of
P. amboinicus on RA. For this reason, P. amboinicus was
studied for its efficacy on RA treatment employing a
collagen-induced rat model, which is commonly used in
the validation of anti-rheumatic drugs because it has
various similarities to human RA (11). Additionally, the
levels of IgG and IgM against self-antigen collagen and
production of inflammatory cytokines, TNF-a, IL-6 and
IL-1b, from peritoneal exudates cells (PECs) were also
determined.
Methods
Sample Preparation and Reagents
Whole plants of P. amboinicus were collected in autumn
in Taitung, Taiwan. Briefly, 100g of P. amboinicus was
ground with 100ml distilled water and filtered using
0.22mM mesh. The filtrate was lyophilized and 100g of
plant yields about 1.66g of solid content (1.66%), and
stored at 20C prior to animal experiments.
Indomethacin was purchased from Johnson Chemical
Pharmaceutical Work LTD (Taiwan, ROC). The bovine
type-II collagen from tracheal cartilage and bovine serum
albumin (BSA) were purchased from Sigma-Aldrich
(St Louis, USA), and complete Freund’s adjuvant
(CFA) was obtained from Difco Laboratories (Detroit,
USA). Indomethacin and P. amboinicus extract powder
were suspended in distilled water and adjusted to the
experimental doses prior to the animal experiment.
All test articles were administered to animals using
gastric tube.
Collagen-induced Arthritic Rat Animal Experiment
For collagen-induced arthritis (CIA) experiments, Lewis
rats, body weight ranging from 155 to 165g, were
purchased from National Laboratory Animal Center
(Taiwan, ROC). Rats were maintained under climate-
controlled conditions under 12h light–dark cycle. The
animals were fed with standard rodent chow (PMI
Nutrition International, USA) and water ad libitum.
Twenty-five rats were divided into five groups as follows:
(i) Normal; (ii) CIA plus vehicle; (iii) CIA plus
Indomethacin (2.5mg/kg); (iv) CIA plus P. amboinicus,
low dosage (75mg/kg); (v) CIA plus P. amboinicus high
dosage (375mg/kg). The induction of arthritis in animals
was performed as described by Campo et al. (12). Briefly,
arthritis in rats was induced by immunization with
collagen type II that was dissolved in 0.1M acetic acid
(2mg/ml) at 4C overnight and emulsified with an equal
volume of CFA. Each rat was immunized with a dose of
200mg collagen type II/0.2ml emulsion intradermally at
the base of the tail. Rats were boosted with the same
antigen preparation on day 14. After the second
immunization, development of rheumatic symptoms was
observed starting from day 18 and rats were administered
test article by gavages starting day 25 for 20 consecutive
days. Blood was withdrawn from tail vein on days 0, 20
and 35, and rats were sacrificed under CO2 euthanasia on
day 45 on which day blood was withdrawn from the
heart. All rats received human care, and the study
protocol followed guidelines of Institutional Animal Care
and Use Committees of the Development Center for
Biotechnology.
Assessments of Arthritic Index and Footpad Thickness
in CIA Rats
A blinded independent observer with no knowledge of
the treatment protocol performed evaluation of joint
inflammation. The severity of arthritis in each footpad
quantified daily by a clinical score measurement. The
level of arthritic inflammation of each paw was graded
from 0 to 4 according to Campo et al. (12). The
maximum arthritic index (MAI) of four paws was
summed for each rat and ranged from 0 to 16 (0, no
disease; 16, highest possible score). The degree of footpad
swelling was measured using a caliper. The increased
thickness of footpad in percentage was compared with
normal rats without immunization of collagen.
Ex vivo Determination of Cytokines Releasing from
Peritoneal Exudates Cells
Peritoneal exudates cells (PEC) were stimulated by
injection with Hank’s balanced salt solution (HBSS)
into abdominal cavity of rats after sacrifice of the
animals and PEC cells were collected by centrifugation.
PEC were cultured in DMEM containing 10% fetal
bovine serum in a 48-well plate at a density of 10
6 cells/
ml at 37C, 5% CO2 for 24h. After incubation, the
culture medium was collected and stored at 20C prior
to cytokine determination. Cytokines were measured by
using enzyme-linked immunosorbent assay (ELISA).
Briefly, the concentrations of inflammatory cytokine
TNF-a, IL-6 and IL-1b in PEC cell culture medium
were quantified by using commercial cytokine ELISA kit
(R&D, DuoSet, MN) and performed in duplicate
according to the manufacturer’s instructions.
Measurement of Serum-specific Anti-Collagen Type II
IgG and IgM Antibody
Blood was allowed to clot for 30min, and serum was
obtained by centrifugation at 800g for 10min that stored
at 20C prior to analysis of anti-collagen type II specific
IgM and IgG antibodies. The method was performed as
Jonsson et al. (13) described with a slight modification.
Briefly, the collagen was coated onto the 96-well plate and
IgM was detected by goat anti-rat IgM conjugated with
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ture follower by staining with tetramethylbenzidine sub-
strate. The optical density was measured with a Multiskan
Ex ELISA reader (Thermo Fisher Scientific, USA) at
450nm and wells without loading serum sample were
regarded as blank. For measurement of IgG, goat anti-rat
IgG Fc HRP-conjugated monoclonal antibody was used,
and the procedure measurements were similar to those
followed for IgM.
Analysis of Serum C-reactive Protein
The level of serum CRP was measured by the commercial
Rat CRP ELISA kit (BD
TM Pharmingen) and each
sample was performed in duplicate according to the
manufacturer’s instructions.
Statistical Analysis
Statistical analysis was performed using one-way
ANOVA to analyze the variances, and significant
difference was evaluated by Dunnett’s test for multiple
comparisons. A P-value less than 0.05 was considered
statistically significant.
Results
P. Amboinicus Prevented Body Weight Loss of CIA Rats
Lewis rats were immunized with the collagen type II on
days 1 and 14. The onset of symptoms of arthritis was
observed around day 20. In collagen-induced arthritic
rats (vehicle group), body weight was not increased in
that the inflammation was induced by self-antigen. In
the group of collagen-induced arthritic rats treated
with indomethacin and high dosage (375mg/kg) of
P. amboinicus, the body weight was normally increased
as in the normal group but decreased in the group treated
with low dosage of P. amboinicus (75mg/kg) and vehicle
control (Fig. 1A).
Ankylosis Significantly Improved in CIA Rats
The arthritic index represents the grade of arthritis that
was used to assess efficacy of P. amboinicus. In the
vehicle group, diseased rats without any treatment
showed an increased arthritic index starting on day 18
to a plateau on day 35. Indomethacin appears to have the
ability to inhibit progression of disease, and the high
dosage of P. amboinicus was also observed to have
significantly strong activity in preventing progression of
arthritic disease (Fig. 1B). However, the low dosage of
P. amboinicus showed moderate efficacy in inhibiting an
increase in arthritic index.
Footpad Swelling Significantly Suppressed in CIA Rats
The swelling of footpad in collagen-induced rat model
also represents the severity of arthritis. In the vehicle
group, thickness of footpad was increased to a maximum
Figure 1. Assessment of body weight, arthritic index and footpad
thickness in CIA rats with P. amboinicus aqueous extract. Effects on
body weight (A), arthritic index (B) and footpad swelling (C)o f
indomethacin and P. amboinicus aqueous extracts (L: 75mg/kg, H:
375mg/kg) in Lewis rats subjected to collagen-induced arthritis (CIA).
**P<0.01 vs. vehicle group (see text).
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footpad thickness was inhibited by indomethacin, high
dosage and low dosage of P. amboinicus by 93.2%,
70.7% and 41.8%, respectively, and the scale of footpad
thickness was set as 100% between the vehicle group and
normal group (Fig. 1C). Indomethacin and the high
dosage of P. amboinicus showed significant inhibitory
activity in footpad swelling. The low dosage of
P. amboinicus also had the ability to inhibit footpad
swelling with moderate effectiveness. These results were
coincident with the observation in arthritic index.
According to these data, the arthritic rats were estab-
lished and responded to the indomethacin.
The Production of Serum Anti-Collagen IgM was
Inhibited by P. Amboinicus in CIA Rats
The serum IgM and IgG levels against self-antigen
collagen are important biomarkers in collagen-induced
arthritis rat model. In this study, we analyzed the serum
IgG and IgM levels in collagen-induced arthritic rats.
Results revealed that serum IgM levels dramatically
increased and achieved a maximum level on day 20
(Fig. 2A). The IgM levels were elevated in collagen-
induced arthritic rat on day 20, and their production
were inhibited up to 51% by indomethacin and to 39%
by the high dosage of PA using the end-point analysis
(day 45). The levels of serum anti-collagen IgG antibodies
were also monitored on day 20, 35 and 45, respectively
(Fig. 2B). Results indicated that the levels of serum anti-
collgen IgG antibodies significantly increased in the
collagen-induced arthritic rats, whereas neither indo-
methacinn nor P. amboinicus had an effect on the
reduction of anti-collagen IgG antibody levels.
The Levels of C-Reactive Protein were Suppressed by
P. Amboinicus in CIA Rats
Serum CRP, a marker of systemic inflammation, is
produced by liver, which is one of the most responsive
acute phase serum reactants. In this study, the high levels
of CRP were induced in the CIA-vehicle group, which
were maintained on a level of 9–12mg/ml. For indo-
methacin treatment, the CRP levels were significantly
suppressed to 2.5mg/ml at day 45. In the high dosage of
P. amboinicus treatment, the levels of serum CRP were
significantly suppressed and gradually decreased (Fig. 3).
These data showed that P. amboinicus had the activity to
decrease the systemic inflammation.
The Secretion of Pro-inflammatory Cytkines in PEC
was Suppressed by P. Amboinicus
The PEC cells were washed out from the abdominal
cavity of rats for the assessment of inflammatory TNF-a,
IL-6 and IL-1b production. Results revealed that
inflammatory cytokines, such as TNF-a, IL-6 and
IL-1b, were increased around 7-fold in collagen-induced
arthritic rats, whereas this elevated cytokine production
was not inhibited by treatment with indomethacin
(Fig. 4A, B and C). Notably, a significant inhibition in
TNF-a, IL-6 and IL-1b production was observed in the
high-dosage group of P. amboinicus, but not in treatment
with indomethacin. It was suggested that P. amboinicus
conferred its ability in treatment of RA via the inhibition
of inflammatory cytokines, which might differ from
effects of indomethacin.
Discussion
When compared with the other arthritic animal models,
arthritis induced by immunization with collagen is a
promising model for validation of the efficacy of anti-
rheumatic drugs (14). The most important index for
evaluation of arthritis is to measure the footpad swelling
Figure 2. Assessment of anti-collagen type II antibody IgM and IgG in
CIA rats with P. amboinicus aqueous extract. Effects on anti-collagen
type II antibody IgM and IgG of indomethacin and P. amboinicus
aqueous extracts (L: 75mg/kg, H: 375mg/kg) in Lewis rats subjected to
collagen-induced arthritis (CIA). **P<0.01 vs. Vehicle group (see text).
118 Anti-RA effect of P. amboinicuswith calipers and visual inspection, and that is not
restricted through different ways to induce arthritis in
animals (15). In this article, P. amboinicus showed the
ability to treat collagen-induced arthritis in rats. The
reduction of CRP was also relevant to inhibiting arthritic
progression. These findings were positively consistent
with the results of histological examinations, which
reduced inflammation lesion and bone erosion in the
high dose of P. amboinicus and indomethacin groups
(data not shown).
According to the production of cytokines from PEC
cells, P. amboinicus might confer its activity differing
from indomethacin that inhibits the cyclooxygenase
enzyme. Recently, Patten and his colleagues (16) reported
that TNF-a, IL-6 and IL-1b were persistently up-
regulated in arthritic joints of the pristane-induced
arthritis, whereas indomethacin failed to reduce the
expression of these pro-inflammatory cytokines. In their
study, only prednisoline significantly reduced these
cytokines and revealed the most effective joint protection.
P. amboinicus might have elicited their anti-RA activity
with different pharmacological action mode to nonster-
oidal anti-inflammatory drugs.
In autoimmune disease, pro-inflammatory cytokines
play an important role in RA and scientists intend to
design drugs for suppression of this disease via anti-
inflammation (4). Currently, therapeutically controlling
inflammation is essential for the clinical management of
many high-prevalence human diseases (17). Drugs that
block pro-inflammatory cytokines, such as TNF-a and
IL-1b, can improve outcomes for RA, and Kineret
and Enbrel have been developed to block IL-1b receptor
and neutralize the TNF-a (18,19); however, these protein
drugs are costly in the treatment of RA (20).
Indomethacin is a cyclooxygenase inhibitor that inhibits
the production of prostaglandins, which this kind of
NSAIDs may cause undesired side-effects, such as
gastrointestinal damages (21). P. amboinicus might
improve the therapeutic efficacy of NSAID or lessen
the use of NSAID for combining with two different
pharmacological action drugs. In addition, the active
ingredients for treatment of RA should be identified and
characterized. For safety, P. amboinicus is used as food
additive and an unpublished data reported that acute
phase toxicity was not observed in rats with one dosage
Figure 4. Ex vivo assessments of TNF-a, IL-1b and IL-6 cytokine
secretion from PEC in CIA rats with P. amboinicus aqueous extract.
Effects on TNF-a, IL-1b and IL-6 of indomethacin and P. amboinicus
aqueous extracts (L: 75mg/kg, H: 375mg/kg) in Lewis rats subjected
to collagen-induced arthritis (CIA). ***P<0.001 vs. Vehicle group
(see text).
Figure 3. Assessment of serum CRP in CIA rats with P. amboinicus
aqueous extract. Effects on CRP of indometacin and P. amboinicus
aqueous extracts (L: 75mg/kg, H: 375mg/kg) in Lewis rats subjected to
collagen-induced arthritis (CIA). **P<0.01 vs. Vehicle group (see text).
eCAM 2010;7(1) 119of 5000mg/kg. In our study, we demonstrated that
the feasibility of P. amboinicus in treating RA and
P. amboinicus might be developed as a disease-modifying
anti-rheumatic drug.
Acknowledgement
This study is supported by a grant from Ministry
of Economic Affairs, Taiwan, ROC (94-EC-17-A-20-
R7-0722).
References
1. Tenney DJ, Levine SM, Rose RE, Walsh AW, Weinheimer SP,
Discotto L, et al. Clinical emergence of entecavir-resistant hepatitis
B virus requires additional substitutions in virus already resistant to
Lamivudine. Antimicrob Agents Chemother 2004;48:3498–507.
2. Jawaheer D, Thomson W, MacGregor AJ, Carthy D, Davidson J,
Dyer PA, et al. ‘‘Homozygosity’’ for the HLA-DR shared epitope
contributes the highest risk for rheumatoid arthritis concordance in
identical twins. Arthritis Rheum 1994;37:681–6.
3. Waller ES. Evaluation of new indomethacin dosage forms.
Pharmacotherapy 1983;3:324–33.
4. Goldenberg MM. Celecoxib, a selective cyclooxygenase-2 inhibitor
for the treatment of rheumatoid arthritis and osteoarthritis. Clin
Ther 1999;21:1497–513discussion 1427–1498.
5. Bertolini A, Ottani A, Sandrini M. Dual acting anti-inflammatory
drugs: a reappraisal. Pharmacol Res 2001;44:437–50.
6. White WB, West CR, Borer JS, Gorelick PB, Lavange L, Pan SX,
et al. Risk of cardiovascular events in patients receiving celecoxib: a
meta-analysis of randomized clinical trials. Am J Cardiol
2007;99:91–8.
7. Lukhoba CW, Simmonds MS, Paton AJ. Plectranthus: a review of
ethnobotanical uses. J Ethnopharmacol 2006;103:1–24.
8. Vera R, Mondon JM, Pieribattesti JC. Chemical Composition of
The Essential Oil and Aqueous Extract of Plectranthus amboinicus.
Planta Med 1993;59:182–3.
9. Harsha VH, Hebbar SS, Shripathi V, Hegde GR.
Ethnomedicobotany of Uttara Kannada District in Karnataka,
India–plants in treatment of skin diseases. J Ethnopharmacol
2003;84:37–40.
10. Chang SL, Chang YC, Yang CH, Hong HS. Allergic contact
dermatitis to Plectranthus amboinicus masquerading as chronic leg
ulcer. Contact Dermatitis 2005;53:356–7.
11. Holmdahl R, Andersson M, Goldschmidt TJ, Gustafsson K,
Jansson L, Mo JA. Type II collagen autoimmunity in animals
and provocations leading to arthritis. Immunol Rev
1990;118:193–232.
12. Campo GM, Avenoso A, Campo S, Ferlazzo AM, Altavilla D,
Calatroni A. Efficacy of treatment with glycosaminoglycans on
experimental collagen-induced arthritis in rats. Arthritis Res Ther
2003;5:R122–31.
13. Jonsson T, Arnason JA, Valdimarsson H. Enzyme-linked immuno-
sorbent assay (ELISA) screening test for detection of rheumatoid
factor. Rheumatol Int 1986;6:199–204.
14. Shou J, Bull CM, Li L, Qian HR, Wei T, Luo S, et al. Identification
of blood biomarkers of rheumatoid arthritis by transcript profiling
of peripheral blood mononuclear cells from the rat collagen-induced
arthritis model. Arthritis Res Ther 2006;8:R28.
15. Mindrescu C, Thorbecke GJ, Klein MJ, Vilcek J, Wisniewski HG.
Amelioration of collagen-induced arthritis in DBA/1J mice by
recombinant TSG-6, a tumor necrosis factor/interleukin-1-inducible
protein. Arthritis Rheum 2000;43:2668–77.
16. Patten C, Bush K, Rioja I, Morgan R, Wooley P, Trill J, et al.
Characterization of pristane-induced arthritis, a murine model of
chronic disease: response to antirheumatic agents, expression of
joint cytokines, and immunopathology. Arthritis Rheum
2004;50:3334–45.
17. Vierboom MP, Zavodny PJ, Chou CC, Tagat JR, Pugliese-Sivo C,
Strizki J, et al. Inhibition of the development of collagen-induced
arthritis in rhesus monkeys by a small molecular weight antagonist
of CCR5. Arthritis Rheum 2005;52:627–36.
18. Calabrese LH. Molecular differences in anticytokine therapies.
Clin Exp Rheumatol 2003;21:241–8.
19. Louie SG, Park B, Yoon H. Biological response modifiers in the
management of rheumatoid arthritis. Am J Health Syst Pharm
2003;60:346–55.
20. Lubeck DP. A review of the direct costs of rheumatoid arthritis:
managed care versus fee-for-service settings. Pharmacoeconomics
2001;19:811–18.
21. Mohamed AH, Salena BJ, Hunt RH. NSAID–induced gastroduo-
denal ulcers: exploring the silent dilemma. J Gastroenterol 1994;29
Suppl 7:34–8.
Received June 23, 2007; accepted September 12, 2007
120 Anti-RA effect of P. amboinicus